Trial · NCT03620578
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
NCT03620578, Phase 2, Unknown, Stichting Hemato-Oncologie voor Volwassenen Nederland
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL. Trials, record NCT03620578. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03620578
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
- NCT number
- NCT03620578
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 97 participants, actual
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Conditions
- Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma, MYC Translocation, BCL-2 Translocation
- Interventions
- DA-EPOCH-R followed by Nivolumab
- First posted
- 2018-08-08
- Last updated
- 2024-02-14
- Other registries' IDs
- eudract:2017-003631-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12 months DFS from Nivolumab consolidation registration | 12 months | 12 months DFS (defined as time from registration for consolidation to disease relapse or death, whichever comes first) of patients in CMR as assessed by end of DA-EPOCH-R treatment 18F-Fludeoxyglucose Positron Emission Tomography- Computed Tomography (18F-FDG PET-CT) |
| Secondary | Complete metabolic response (CMR) rate on 18F-FDG PET-CT after DA-EPOCH-R | at 18 weeks | CMR rate on 18F-FDG PET-CT after DA-EPOCH-R |
| Secondary | 18 months Progression-Free Survival (PFS) | 18 months | 18 months PFS (defined as time from registration to disease progression, relapse or death, whichever comes first) |
| Secondary | 18 months OS | 18 months | 18 months OS (defined as time from registration until death from any cause; patients still alive or lost to follow up are censored at the date they were last known to be alive) of all patients |
| Secondary | 12 months OSc | 12 months | 12 months overall survival under consolidation (OSc), defined as time from registration for consolidation until death from any cause. Patients still alive or lost to follow up are censored at the date they were last known to be alive |
| Secondary | Rate of CTCAE grade >=2 toxicities | During 70 weeks treatment + 100 additional days during follow up | Rate of CTCAE grade \>=2 toxicities |
| Secondary | consolidation MRD conversion | 12 months | Rate of conversion to MRD negativity during consolidation |
| Secondary | predictive value of mid-treatment 18F-FDG PET-CT | 2 months | Assessment of the predictive value of mid-treatment 18F-FDG PET-CT with respect to CMR at the end of DA-EPOCH-R therapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03620578
GET https://conductscience.org/api/trials/v1/NCT03620578/registered